Fresenius SE & Co. KGaA (OTCMKTS:FSNUY – Get Rating) has been assigned an average rating of “Hold” from the eleven research firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $50.91.
FSNUY has been the topic of several recent analyst reports. Societe Generale decreased their target price on Fresenius SE & Co. KGaA from €94.00 ($97.92) to €87.00 ($90.63) and set a “buy” rating on the stock in a research note on Friday, February 25th. Berenberg Bank lifted their target price on Fresenius SE & Co. KGaA from €55.95 ($58.28) to €60.25 ($62.76) and gave the company a “buy” rating in a research note on Wednesday, February 16th. HSBC downgraded Fresenius SE & Co. KGaA from a “buy” rating to a “hold” rating in a research note on Tuesday, May 10th. JPMorgan Chase & Co. decreased their target price on Fresenius SE & Co. KGaA from €34.50 ($35.94) to €33.30 ($34.69) and set a “neutral” rating on the stock in a research note on Friday, May 13th. Finally, Deutsche Bank Aktiengesellschaft cut their price target on Fresenius SE & Co. KGaA from €38.00 ($39.58) to €36.00 ($37.50) and set a “hold” rating for the company in a report on Friday, February 25th.
Shares of OTCMKTS FSNUY traded up $0.13 during trading on Friday, hitting $8.63. The company had a trading volume of 65,276 shares, compared to its average volume of 119,325. The stock has a 50 day simple moving average of $9.06 and a 200 day simple moving average of $9.65. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.85 and a current ratio of 1.13. Fresenius SE & Co. KGaA has a 12 month low of $7.37 and a 12 month high of $14.81. The firm has a market capitalization of $19.28 billion, a P/E ratio of 8.90 and a beta of 1.24.
About Fresenius SE & Co. KGaA (Get Rating)
Fresenius SE & Co KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
- Get a free copy of the StockNews.com research report on Fresenius SE & Co. KGaA (FSNUY)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for Fresenius SE & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.